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Release of selected amino acids from zinc carriers
The paper deals with the results of an investigation of the 
release of selected amino acids (histidine, tryptophan, ty-
rosine) from model suspensions prepared by co-precipita-
tion with zinc chloride. It has been proven that the influ-
ence of the Zn(II)/amino acid molar ratio on dissolution 
profiles of the tested amino acids and dissolution half-life 
(t1/2) of histidine or tryptophan is significant. The amount 
of amino acid in the dispersed phase (supporting dose) is a 
determinant of the amino acid release profile. There is a 
minimal supporting dose (30.0 μmol of histidine or 17.4 
μmol of tryptophan) that provides release of similar 
amounts of amino acid (4.1–4.6 μmol of histidine or 8.7–9.9 
μmol of tryptophan) after the same time intervals. The ty-
rosine release profiles follow first order kinetics since the 
supporting dose (0.9–11.2 μmol) is limited by the tyrosine 
low solubility in water.
Keywords: amino acids, zinc, suspensions, dissolution, ki-
netics
Zinc in conjunction with protein, peptides or low molecular weight substances in the 
form of suspension provides prolonged drug action (1–6). Co-precipitation with zinc salts 
is one of the methods for obtaining sustained release drug carriers (4, 5). Co-precipitation 
involves intercalation of a low-molecular weight drug molecule into layered zinc hydrox-
ide, layered zinc hydroxide salt, or layered double hydroxide (4–7). Sparingly soluble zinc 
compounds form matrices for sustained release of p-coumaric acid, levodopa (4, 5). These 
carriers are biocompatible and are an attractive alternative to other sustained release drug 
formulations (5).
Amino acids (AAs) are used as model substances in studies on suspensions (6–9). AA 
bound in the dispersed phase is a model of the supporting dose that slowly releases the 
drug. Zn(II)/drug molar ratio determines the dissolution profile of a suspension prepared 
by the co-precipitation method (3, 8).
On the basis of preliminary experiments, optimal variants of suspensions were ob-
tained by co-precipitation of selected amino acids with zinc chloride. The most probable 
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salt. AAs-histidine (His), tryptophan (Trp) and tyrosine (Tyr) served as model substances. 
Influence of the Zn(II)/AA molar ratio on the release of AA from suspensions was investi-




L-Histidine (His, C6H9N3O2, ≥ 99 % pure; Mr = 155.15), L-tryptophan (Trp C11H12N2O2, 
≥ 98 % pure; Mr = 204.23, pI = 5.89) and L-tyrosine (Tyr C9H11NO3, ≥ 98 % pure; Mr = 181.19, 
pI = 5.66) were purchased from Sigma Chemical Corp., USA. All other reagents were sup-
plied by Avantor Performance Materials Poland S.A., Poland (formerly POCH, Poland). 
The reagents satisfied the requirements of the standards.
Preparation of AA-Zn(II) suspensions
AA (His, Trp or Tyr) was dissolved in 0.015 mol L–1 HCl solution. Amount of 0.75 mL 
of 0.1 mol L–1 ZnCl2 in 0.003 mol L–1 HCl solution was mixed with 5 mL of 0.001, 0.005, 0.006, 
0.01 or 0.02 mol L–1 AA solution yielding Zn(II)/AA molar ratios 15:1, 3:1, 2.5:1, 1.5:1 or 0.75:1, 
respectively. 0.75:1 Zn(II)/Tyr molar ratio was not obtained because of the limited solubil-
ity of Tyr in 0.015 mol L–1 HCl. Then, 1.05–1.35 mL of 0.2 mol L–1 NaOH solution was added. 
The volume of added 0.2 mol L–1 NaOH solution provided the optimal pH value for AA 
binding in the dispersed phase and was determined on the basis of preliminary experi-
ments. Total volume was adjusted to 10.0 mL with distilled water. The suspensions were 
stirred using a magnetic stirrer at 500 rpm for 25 min. The suspensions were then left at 
room temperature for 1 h.
Optical microscopy of AA-Zn(II) suspensions
Optical microscope (MT 4000 Series Meiji Techno Co. LTP, Japan) was used to study 
the particle size of the suspension. A drop of undiluted formulation was viewed using 
total magnification of 100 or 400×.
Characterization of AA-Zn(II) suspensions
The suspensions (10 mL) were centrifuged for 10 minutes at 4000 rpm. The pH values, 
concentrations of AA and Zn(II) were then determined in the supernatant. The amounts 
of AA (supporting dose) and Zn(II) in the dispersed phase were calculated as the differ-
ence between the initial amount and those determined in the supernatant. The precipitate 
was intended for use in the in vitro release study of AA.
In vitro release study of AA from suspensions
The precipitate was re-suspended in 10 mL of 0.9 % NaCl solution and stirred with a 
magnetic stirrer at 500 rpm for 30 min. The suspension was subjected to centrifugation at 
4000 rpm for 10 min and the amount of dissolved AA was determined in the supernatant. 
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The precipitate was re-suspended in 10 ml of fresh 0.9 % NaCl solution and the procedure 
was repeated. The study was carried out until dissolution of 95 % of the AA supporting 
dose or for 5 h.
Spectrophotometric determination of AA
Absorbance (x) was measured in 1 cm quartz cuvettes using a CE 3021 UV-Vis spec-
trometer (Cecil, UK). The photometric accuracy of the spectrophotometer was ± 0.005. AA 
concentration (y) was calculated on the basis of regression equations (His y = 0.0387x + 
0.0053 R2 > 0.999; Trp y = 0.1758x + 0.0087 R2 > 0.999; Tyr y = 0.0466x + 0.0256 R2 > 0.999). 
Absorbance was measured at wavelengths (λmax) at which maximum absorbance was ob-
served (λmax(His) = 211.0 nm, λmax(Trp) = 218.5 nm, λmax(Tyr) = 222.5 nm).
Complexometric determination of Zn(II)
Zn(II) was determined by complexometric titration using 0.05 mol L–1 EDTA in the 
presence of Eriochrome Black T in pH 10 ammonia buffer until the initially violet solution 
turned blue (Polish Pharmacopeia VI).
Determination of pH values
pH values were measured using a Microcomputer pH-meter CP-315 (POCH, Poland). 
The electrode was calibrated using 0.05 mol L–1 sodium phosphate buffer solution pur-
chased in Chempur, Poland.
Analysis of AA release data
The release kinetics of AA from the suspensions were elucidated by fitting the release 
data to kinetic models (first order or zero order) (Table I) and by comparison of the squared 
correlation coefficients R2 values. AA dissolution half-lives (t1/2, h) were calculated accord-
ing to the kinetics with the higher value of R2 (Table I).
Data analysis
The results were presented as the mean value (x ± SD) of 5 experiments and were ana-
lyzed using Excel (Microsoft Office) and Statistica 10 (Statsoft) computer programs. The 
influence of Zn(II)/AA on selected parameters was analyzed using ANOVA and Tukey’s 
Table I. First order kinetics, zero order kinetics and Korsmeyer-Peppas equations (10)
First order kinetics Zero order kinetics  Korsmeyer-Peppas model
Linear equation ln (100–Q) = – k1t + ln 100 Q = kot ln (Mt/M∞) = ln k + n ln t
t1/2 t1/2 = 0.693/k1 t1/2= 50/ko
Q – percent of AA released after time I (h); k1 – first order release constant (1/h); ko – zero order release constant 
(%/h), t1/2 – dissolution half-life (h), Mt/M∞ – fraction of AA released at time t (h); n – Korsmeyer-Peppas diffusion 
exponent.
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post-hoc test. The influence of the Zn(II)/AA molar ratio on dissolution profiles of AA was 
analyzed using ANOVA. The level of statistical significance was p < 0.05.
Determination and evaluation of theoretical AA release profiles
Theoretical AA release profiles were determined on the basis of the plot of the amount 
of AA released after the first 0.5 h against the amount of AA in the dispersed phase (AA 
supporting dose). Theoretical amount of AA released after the 0.5 h interval (y) corre-
sponded to the remaining amount of AA (new supporting dose) (x). Similarity of theo-
retical and empirical AA release profiles was tested by means of relative error δx, which 
was calculated by the equation:
 , where
j is a number of time points, n is a total number of time points, xj is amount of AA released 
during 0.5 h at time point j (%) (curve 1) and yj is amount of AA released during 0.5 h at 
time point j (%) (curve 2).
Dissolution profiles were also compared using a model independent method. Fit fac-
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where j is a number of time points, n is a total number of time points, Rj and Tj are cumula-
tive percent of AA dissolved at each time point (curve 1 and curve 2, respectively).
According to the FDA guide for industry, f1’ values up to 15 (0–15) and f2 values great-
er than 50 (50–100) ensure sameness or equivalence of the two curves (11).
RESULTS AND DISCUSSION
Properties of the obtained suspensions (pH value, AA and Zn(II) concentration in the 
dispersed phase and particle size) are summarized in Table II.
Parenteral suspensions with protein-peptide hormones should be in the pH range 
7.10–7.50. For research purposes and in order to obtain suspensions with the optimal 
amount of AA bound in the dispersed phase, the extended pH range was applied. Percent 
of AA bound in the dispersed phase was 57.3–84.4 % (His), 48.4–84.4 % (Trp) and 17.0–36.1 % 
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7.01–7.79 (Trp) and 7.90–7.98 (Tyr) (Table II). The amount of Zn(II) bound (%) as the matrix 
of the dispersed phase was higher than 79 % (except for Zn(II)/His 0.75:1 suspension) (Ta-
ble II).
The particle size of the dispersed phase of Zn(II)/His 15:1, 3:1, Zn(II)/Tyr 15:1, 3:1 and 
1.5:1 and Zn(II)/Trp 15:1 suspensions was 1–5 mm and was smaller than 1 mm in the case of 
Zn(II)/His 1.5:1 and Zn(II)/His 0.75:1 suspensions. Zn(II)/Trp 3:1, 2.5:1, 1.5:1, 0.75:1 suspen-
sions included, besides amorphous particles, ordered spherical aggregates with particle 
sizes 1–25 mm (Table II).
Fig. 1 depicts the influence of the amount of AA in the dispersed phase (supporting 
dose) on the amount of AA released from suspensions after 0.5 h. Theoretical AA release 
profiles were calculated on the basis of Fig. 1.
Table II. Properties of the AA-Zn(II) suspensions












15:1 0.5 7.5 8.24 ± 0.02 0.3 ± 0.0 7.1 ± 0.2 1–5
3:1 2.5 7.5 9.82 ± 0.02 1.7 ± 0.0 6.2 ± 0.0 1–5
1.5:1 5.0 7.5 9.33 ± 0.03 4.2 ± 0.0 7.1 ± 0.0 < 1
0.75:1 10.0 7.5 9.90 ± 0.00 5.7 ± 0.1 5.1 ± 0.2 < 1
Trp
15:1 0.5 7.5 7.01 ± 0.00 0.2 ± 0.0 6.0 ± 0.0 1–5
3:1 2.5 7.5 7.34 ± 0.03 1.2 ± 0.0 6.2 ± 0.0 1–5 (aggregates 1–5)
2.5:1 3.0 7.5 7.43 ± 0.03 1.7 ± 0.0 6.5 ± 0.0 1–5 (aggregates 1–10)
1.5:1 5.0 7.5 7.48 ± 0.02 4.2 ± 0.0 6.7 ± 0.0 1–10 (aggregates 1–10)
0.75:1 10.0 7.5 7.79 ± 0.02 8.3 ± 0.1 7.0 ± 0.0 1–25 (aggregates 5–25)
Tyr
15:1 0.5 7.5 7.91 ± 0.02 0.1 ± 0.0 7.2 ± 0.0 1–5
3:1 2.5 7.5 7.90 ± 0.03 0.9 ± 0.1 6.7 ± 0.2 1–5
1.5:1 5.0 7.5 7.98 ± 0.05 1.2 ± 0.0 6.2 ± 0.0 15
a initial concentration
b concentration of amino acid or Zn(II) bound in the dispersed phase
Fig. 1. The amount of AA released from suspensions after 0.5 h against the amount of AA in the dispersed 
phase (supporting dose). Theoretical AA release profiles were calculated on the basis of the graph.
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Suspensions with 30–57 μmol His and 17–83 μmol Trp in the dispersed phase released 
similar amounts of AA after 0.5 h (4.1–4.6 μmol His and 8.7–9.9 μmol Trp). Suspensions 
with smaller amounts of AA in the dispersed phase released smaller amounts of AA after 
0.5 h. However, the amount of Tyr released after 0.5 h was directly proportional to the 
amount of Tyr in the dispersed phase (Fig. 1).
Fig. 2 shows AA release profiles and Fig. 3 shows cumulative AA release profiles. 
Theoretical AA release profiles (calculated from Fig. 1) are also marked (Figs. 2 and 3). 
Relative error values δx < 20 % and fit factor values (f1’< 15 and f2 > 50) confirmed the simi-
larity of theoretical and empirical AA release profiles. This indicates that the amount of 
AA in the dispersed phase (maintenance dose) is the factor determining the AA release 
profile.
ANOVA showed a significant effect of the Zn(II)/AA molar ratio on the cumulative AA 
release (%) (p < 0.05).
Kinetic analysis of the AA release data (first order and zero order R2 squared coeffi-
cients, t1/2 (h) and Korsmeyer-Peppas diffusion exponent n values) is given in Table III. The 
data calculated from the theoretical dissolution profiles are also summarized in Table III 
(in parentheses).
Release kinetics (zero order or first order) was determined on the basis of the R2 cor-
relation coefficients and Korsmeyer-Peppas diffusion exponent n values (Table III). Kors-
meyer-Peppas diffusion exponent n value equal to 1.0 is indicative of zero order kinetics 
(10). Release of AA from the Zn(II)/His 0.75:1 (R2 = 0.9995, n = 0.96), Zn(II)/His 1.5:1 (R2 = 
Fig. 2. The amount of AA (Q (mmol)) released over 0.5 h at specific time points. Suspensions with dif-
ferent Zn(II)/AA molar ratios: a) Zn(II)/AA 15:1, b) Zn(II)/AA 3:1, c) Zn(II)/AA 1.5:1 and d) Zn(II)/AA 
0.75:1. Lines mark theoretical AA release profiles.
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Fig. 3. Cumulative AA release profiles Q (%) vs. t(h); suspensions with different Zn(II)/AA molar ratios 
for: a) His, b) Trp and c) Tyr. Lines mark theoretical AA release profiles.
Table III. Kinetic analysis of the in vitro release data of His, Trp and Tyr from suspensions; values of R2 
correlation coefficients, t1/2 (h) and Korsmeyer-Peppas diffusion exponent n calculated from the theoretical 
dissolution profiles (in parentheses)











15:1 0.324 (0.795) 0.000 (0.216) 2.77 ± 0.17 (2.31) 0.45 (0.52)
3:1 0.950 (0.998) 0.575 (0.699) 2.15 ± 0.02 (1.48) 0.59 (0.68)
1.5:1 0.926 (0.956) 0.982 (0.987) 2.59 ± 0.02 (2.86) 0.96 (0.97)
0.75:1 0.937 (0.950) > 0.999 (> 0.999) 3.43 ± 0.04 (3.65) 0.96 (1.01)
Trp
15:1 0.924 (0.934) 0.094 (0.050) 1.33 ± 0.18 (1.37) 0.51 (0.49)
3:1 0.944 (0.999) 0.703 (0.613) 0.71 ± 0.12 (1.01) 0.65 (0.57)
1.5:1 0.758 (0.987) 0.092 (0.387) 1.21 ± 0.16 (0.93) 0.61 (0.65)
0.75:1 0.735 (0.873) 0.993 (0.992) 2.14 ± 0.02 (2.30) 0.99 (0.95)
Tyr
15:1 0.986 (0.972) 0.000 (0.190) 0.35 ± 0.07 (0.37) 0.37 (0.29)
3:1 0.971 (0.998) 0.161 (0.000) 0.48 ± 0.09 (0.43) 0.48 (0.41)
1.5:1 0.993 (0.999) 0.000 (0.000) 0.52 ± 0.06 (0.45) 0.41 (0.40)
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0.982, n = 0.96) and Zn(II)/Trp 0.75:1 (R2 = 0.993, n = 0.99) suspensions followed zero order 
kinetics, since the suspensions with higher AA supporting dose (> 30.0 μmol of His or > 
17.4 μmol of Trp in the dispersed phase) released similar amounts of AA after 0.5 h (4.1–4.6 
μmol of His or 8.7–9.9 μmol of Trp) (Fig. 1). Release of AA from the Zn(II)/His 15:1 or Zn(II)/
Trp 1.5:1 suspensions followed neither zero order nor first order kinetics (Table III). The 
release of His from Zn(II)/His 15:1 was incomplete (61.5 %) (Fig. 3a). Release of Trp from the 
Zn(II)/Trp 1.5:1 suspension followed initially zero order kinetics (64.85 % of Trp supporting 
dose) as the amount of Trp in the dispersed phase was greater than 17.4 μmol during the 
first 2 h. Trp release was then reduced as the amount of Trp in the dispersed phase dropped 
below 17.4 μmol (Fig. 2c). In other cases, the release of AA from His-Zn(II), Trp-Zn(II) or 
Tyr-Zn(II) suspensions followed first order kinetics (R2 > 0.900 (Table III). No release of Tyr 
following zero order kinetics was obtained because of the small amount of Tyr in the dis-
persed phase (0.9–11.2 μmol). Obtaining Tyr-Zn(II) suspensions with higher Tyr support-
ing dose was limited due to the low solubility of Tyr in water.
Release kinetics (zero order or first order) could be also determined on the basis of the 
theoretical AA release profiles; calculated R2 values are summarized in Table III.
ANOVA showed a significant effect of the Zn(II)/AA molar ratio on the Korsmeyer-
Peppas diffusion exponent n value in the case of all three AA (p < 0.05). However, Zn(II)/
His 1.5:1 and Zn(II)/His 0.75:1 suspensions (p = 0.93) or Zn(II)/Trp 3:1 and Zn(II)/Trp 1.5:1 
suspensions (p = 0.11) had the same n value. The n values were close to 0.5 in case of all 
tested Tyr-Zn(II) suspensions (n = 0.37–0.48), Zn(II)/His 15:1 suspension (n = 0.45) and 
Zn(II)/Trp 15:1 suspension (n = 0.51) indicating a Fickian diffusion mechanism (10). The n 
values less than 0.5 can be explained by the release of AA removably adsorbed on the zinc 
hydroxide surface.
 The t1/2 values calculated according to the kinetics with higher R2 value are sum-
marized in Table III. ANOVA showed a significant effect (p < 0.05) of the Zn(II)/AA molar 
ratio on the t1/2 value (His-Zn(II) or Trp-Zn(II) suspensions). However, Zn(II)/AA 1.5:1 and 
15:1 Zn(II)/AA suspensions had the same t1/2 value (His, p = 0.31; Trp, p = 0.72). Zn(II)/Tyr 
effect on the t1/2 value was not significant (p = 0.08).
CONCLUSIONS
The amount of amino acid in the dispersed phase (supporting dose) is the determin-
ing factor of the release profile. There is a minimal supporting dose that provides the re-
lease of similar amounts of amino acid after the same time intervals (zero order kinetics).
Amino acid solubility in water is a limiting factor for obtaining suspensions with a 
supporting dose high enough to provide a release profile following zero order kinetics and 
sustained release.
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